Lead candidate buntanetap is in Phase 3 testing for early Parkinson's disease and Phase 2/3 study for mild-to-moderate Alzheimer's disease, noted the analyst, who calls PD and AD "high-risk/high-reward indications" with high unmet need. The firm argues that success even in one of these indications "could drive significant upside if data-related events play out favorably."
https://finance.yahoo.com/news/uber-lyft-downgraded-wall-streets-144108349.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.